转移性激素敏感性前列腺癌全身治疗的成本-效果分析
该研究建立状态转移模型模拟转移性前列腺癌自然进程,比较多西他赛+雄激素剥夺治疗(ADT)、阿比特龙+ADT与单用ADT的成本-效果。结果显示多西他赛+ADT的增量成本-效果比(ICER)为34723美元,阿比特龙为295212美元;阿比特龙月成本需低于3114美元才具成本效果。
要点
- 多西他赛+ADT的ICER为34723美元,阿比特龙+ADT为295212美元。
- 阿比特龙月成本需低于3114美元才具成本效果。
- 多西他赛+ADT可能是转移性激素敏感性前列腺癌最具成本效果的选择。
核心结论
- 多西他赛+ADT可能是转移性激素敏感性前列腺癌男性最具成本效果的治疗选择。
- 阿比特龙虽然可能比多西他赛更有效,但其成本需大幅降低才能与多西他赛+ADT的成本效果相匹配。
研究设计与样本
- 研究建立状态转移模型模拟转移性前列腺癌的自然进展。
- 模型参数来自已发表文献并通过校准至观察性流行病学数据获得。
- 假设的转移性激素敏感性前列腺癌男性队列可接受多西他赛+ADT、阿比特龙+ADT或单用ADT治疗,疾病进展至去势抵抗性前列腺癌后开始接受该阶段已批准的治疗。
主要发现
- 与单用ADT相比,多西他赛和ADT联合治疗获得3.6个质量调整生命月的贴现质量调整生存增益。
- 与单用ADT相比,阿比特龙和ADT联合治疗获得22.0个质量调整生命月的贴现质量调整生存增益。
- 多西他赛+ADT的ICER为34723美元,阿比特龙+ADT的ICER为295212美元。
关键数值与推荐
- 多西他赛+ADT的ICER为34723美元,阿比特龙+ADT的ICER为295212美元(美国私人支付方、卫生部门视角)。
- 阿比特龙月成本需低于3114美元才具成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following the recent publication of results from randomized trials that have demonstrated a survival benefit for the addition of docetaxel or abiraterone acetate to androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer, it is important to assess whether the benefits of treatment with these agents outweigh their costs. OBJECTIVE: To perform a cost-effectiveness analysis of immediate docetaxel or abiraterone acetate treatment in addition to ADT in men with metastatic hormone-sensitive prostate cancer (PC). DESIGN, SETTING, AND PARTICIPANTS: We developed a state-transition model to simulate the natural progression of metastatic PC. Model parameters were derived from the published literature and through calibration to observed epidemiological data. Following diagnosis, a hypothetical cohort of men with metastatic hormone-sensitive PC could be treated with docetaxel+ADT, abiraterone+ADT, or ADT alone. Once disease progresses to castration-resistant PC, treatment with one of the approved therapies in this setting was initiated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcomes measured were quality-adjusted life years (QALYs) and costs from a US private payer, health sector perspective. RESULTS AND LIMITATIONS: Compared to treatment with ADT alone, docetaxel and abiraterone resulted in a discounted quality-adjusted survival gain of 3.6 and 22.0mo, respectively. Using standard cost-effectiveness metrics, treatment with docetaxel and ADT provides high value for money (ie, is cost effective) with an incremental cost-effectiveness ratio (ICER) of $34723, compared to an ICER of $295212 for abiraterone. The monthly cost of abiraterone would have to be less than $3114 for it to be cost effective. CONCLUSIONS: Docetaxel+ADT is likely the most cost-effective treatment option for men with metastatic hormone-sensitive PC. Although potentially more effective than docetaxel, the costs of abiraterone would have to be considerably lower to match the cost effectiveness of docetaxel+ADT. PATIENT SUMMARY: This study evaluated the balance of costs and benefits for treatment of metastatic hormone-sensitive prostate cancer with docetaxel plus androgen deprivation therapy (ADT), abiraterone plus ADT, or ADT alone. We found that treatment with docetaxel plus ADT likely represents the most cost-effective option in this setting.
引用
- Sathianathen NJ, Alarid-Escudero F, Kuntz KM, et al. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31411985. doi:10.1016/j.euo.2019.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。